Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III Melanoma
Axel Hauschild(University Hospital Schleswig-Holstein), Georgina V. Long(The University of Sydney), Jacob Schachter, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Thierry Lesimple, Dirk Schadendorf(Essen University Hospital), Kohinoor Dasgupta(Heidelberg University), T Haas(Novartis (United States)), Ruth Plummer(National Health Service), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Eduard Gasal, Richard Kefford(Broad Institute), James Larkin(Royal Marsden NHS Foundation Trust), Laurent Mortier, Mark Shilkrut(Heidelberg University), Victoria Atkinson(The University of Queensland), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Andrew Haydon(The Alfred Hospital), John M. Kirkwood(UPMC Hillman Cancer Center), Caroline Robert(Université Paris-Sud), Mario Mandalà(University of Perugia)
Cited by 255
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k